1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Chris Behrenbruch from Telix Pharmaceuticals sets out a bullish outlook for the radiopharmaceutical group, despite recent regulatory headwinds. Behrenbruch highlights three strategic pillars for 2026: expanding the precision medicine imaging franchise, launching new products, and progressing late-stage therapeutics in prostate, brain and musculoskeletal cancers. Telix’s precision imaging portfolio, led by its prostate cancer agents Illuccix and recently approved Ga-68 PSMA product (Gozellix), is described as the core revenue engine funding a growing therapeutics pipeline.
Behrenbruch states that Telix is guiding to US$950–970 million in revenue for 2026, with around US$200–240 million earmarked for R&D, about 70% directed to therapeutics. He characterises regulatory delays for brain imaging agent Pixclara and another product as temporary “speed bumps”, noting Pixclara has been resubmitted to the US Food and Drug Administration and filed in Europe. He expects Telix to have four approved products by year-end, with more meaningful earnings leverage emerging from 2028 as therapeutics launch.
On the share price, Behrenbruch attributes weakness to the FDA response letter for Pixclara and broader macro uncertainty, but anticipates sentiment improvement as approvals are secured and guidance potentially upgraded. He also flags rising energy and logistics costs, while pointing to initiatives such as solar EV fleets to offset transport pressures.
*partner content
